Scionti Prostate Center
The most experienced prostate treatment focal therapies doctor in the US—over 20 years, and thousands of patients treated.
Our Experience Sets Us Apart
Dr. Scionti is the most experienced TULSA and HIFU physician in the United States, with over 20 years of TUSLA and HIFU experience and 4,000 procedures.
He is the former Director of Prostate Cancer Ablative Surgery at NYU Medical Center and the Medical Director for Vituro Health. He now serves as the Prostate Cancer Program Director for HALO Precision Diagnostics, along with a world-class team of clinicians that deliver comprehensive, precision-focused healthcare.
Dr. Scionti and our science and technology partners have achieved breakthroughs in men’s health with diagnostic testing, early cancer detection, and minimally invasive therapies.
Early detection saves lives
1 https://www.who.int/news-room/facts-in-pictures/detail/cancer 2 Cancer.org 3 Biomarkers and MRI for early PCa detection, https://pubmed.ncbi.nim.nih.gov/32897802 4 seer.cancer.gov
Our Patients Share Their Stories
If you have been diagnosed with Prostate Cancer I strongly recommend that you get in touch with Dr. Scionti and see if you qualify for the HIFU procedure. I believe that it is the best option for a bad situation.
I investigated HIFU on the internet for a different approach to my medical issues. Thank God that I consulted with Dr. Scionti for a different solution to my problem. I had a 3T MRI and a targeted biopsy with Dr. Scionti to accurately localize my cancer. I had the HIFU procedure done on my prostate without any complications of sexual dysfunction or incontinence or pain. I went back to work and playing golf immediately. I am 4 1/2 years post-op, and I have been checked yearly by Dr. Scionti for any recurrence of my cancer with a 3T MRI or an occasional 3T MRI guided biopsy. All is well.
I am so grateful to Dr. Scionti for preserving my life and happiness. His expertise and knowledge of Prostate cancer and treatment are state of the art. Why have sexual dysfunction and incontinence if there is another option?
He prepared us for every aspect of the process, and we understood what to expect. It was better than we expected.After the post-HIFU office visit, my wife and I picked up a nice bottle of wine on the way home to enjoy with dinner.That night I slept well, and the next morning after breakfast went for a short, easy two mile run. It has been just over three years since the HIFU. My life is normal. I exercise as always. Sleep through the night. Have no discomfort. For me HIFU was a wise choice. My experience with Dr. Scionti has been excellent.
of men’s health.
Our team takes a personalized approach to care, guiding patients throughout each phase of genetic testing, screening, diagnosis, and therapies. HALO Precision Diagnostic’s clinical ensemble is changing the way healthcare happens, offering a full view into each patient’s profile and providing physicians with keyinsights designed to better diagnose,understand, treat, and prevent disease.
Over the past 20 years Dr. Stephen Scionti has developed the largest and most experienced practice for prostate cancer treatment using minimally invasive thermal ablation technologies such as HIFU, TULSA-Pro, Cryoablation and Prostate Laser Ablation.
He has achieved global recognition for his experience, skill and groundbreaking clinical contributions in the field of image-guided prostate cancer ablation. He is also an internationally recognized authority in innovative prostate cancer diagnostics. Beyond his practice, Dr. Scionti actively researches and lectures on the outcomes and technology associated with minimally invasive prostate HIFU therapy ablation.
Dr. Scionti formerly served as Clinical Associate Professor of Urology and Director of Prostate Cancer Ablation Surgery at the Joel E. Smilow Comprehensive Prostate Cancer located at the New York University School of Medicine and Langone Medical Center. Prior to his NYU appointment, he was medical director and founder of the Hilton Head, SC International Center for Men’s Health.
About Prostate Cancer Treatments
Concerns about prostate cancer are understandable, but prostate cancer is highly treatable. With the best interventions, most men continue to lead active, healthy lives many years after treatment. The diagnostic tools and treatment options we offer are among the latest and best medical advances available today.
We offer three different options for prostate cancer treatment.
Most Experienced, By Far
By far the most experienced doctor in focal therapies for the treatment of prostate cancer, Dr. Scionti is a pioneer in the field. He has performed more than 4,000 focal ablations over 20 years.
Broader than Focal, Less than Total
TULSA-PRO is a customizable, predictable, and incision-free procedure that allows the doctor to tailor the ablation to each patient.
Transurethral ultrasound ablation (TULSA-PRO) can more easily cover a wider area than laser focal therapy (LFT) / focal laser ablation (FLA). For patients who have a relatively larger cancer or somewhat diffuse cancer within the prostate, TULSA-PRO can cover almost the entire prostate gland in many patients.
Advantages of TULSA-PRO
Decreased Risk of Side Effects
TULSA-PRO has a decreased risk of erectile and urinary side effects compared to whole-gland therapy.
Same-Day Outpatient Procedure
TULSA-PRO is performed in a single session that takes a few hours.
Lets You Keep Your Options Open
If you are in need of future prostate care, you may either have a repeat TULSA Procedure or choose any other type of prostate therapy to address your prostate needs.
Advanced Image Guidance
Directional thermal ultrasound and MR imaging with active heat monitoring.
Customizable Treatment Plans
TULSA-PRO is customizable and personalized based on your situation and goals.
Shared Decision Making
Before your TULSA procedure, you will decide with your physician on a treatment plan.
1 Hatiboglu G, Popeneciu V, Bonekamp D, Burtnyk M, Staruch R, Distler F, Radtke JP, Motsch J, Schlemmer HP, Pahernik S and Nyarangi-Dix J (2021) Single-Center Evaluation of Treatment Success Using Two Different Protocols for MRI–Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer. Front. Oncol. 11:782546. doi: 10.3389/fonc.2021.782546 | 2 Nair, S.M., Stern, N., Dewar, M. et al. (2020). Salvage open radical prostatectomy for recurrent prostate cancer following MRI-guided transurethral ultrasound ablation (TULSA) of the prostate: Feasibility and efficacy. Scandinavian Journal of Urology, 54(3), 215-219. doi: 10.1080/21681805.2020.1752795
Prostate cancer is a common cancer that typically grows slowly and often doesn’t require treatment. However, for a small percentage of men, this disease can be aggressive and spread quickly to other parts of the body.
The only way to know if you are in a high-risk group or have prostate cancer is to get screened regularly.
At HALO Precision Diagnostics, our individualized approach to screening is based on your age, family history, ethnicity, and lifestyle.
We are proud to offer advanced diagnostics that incorporate the four most important new technologies:
- Urine Biomarkers
- 3T Multiparametric MR Imaging & 3D Prostate Mapping
- Fusion-Guided Targeted Biopsy and 3D Tumor Mapping Genomics
- Blood Test
If your prostate screenings have indicated the presence of cancer, the next step is a biopsy to identify what type of cancer is present. At HALO Precision Diagnostics, we use the most advanced technologies like MRI-guided biopsy. Targeted biopsies have been shown to improve detection of aggressive prostate cancers.1
Our state-of-the-art diagnostic approaches include:
- MRI-guided biopsy
- MRI/Ultrasound Fusion Guided Biopsy
Additionally, we offer genetic testing to further diagnose what type of cancer is present and to help determine the most personalizedtreatment approach.
Positive biopsy results can be sent to reveal the underlying biology of the tumor and determine a genomic risk score.
1. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA. 2015;313(4):390-397.